A Personalized Breast Cancer Genomic Profile
No two breast tumors are exactly the same. That’s why different patients respond differently to different treatments. Agendia set out to develop personalized breast cancer diagnostic tests that addresses these differences, and show breast cancer patients what treatments will or will not respond to their specific tumor.
Newly diagnosed breast cancer patients want to know as much as possible about their specific tumor. For women with early-stage breast cancer, the Agendia Breast Cancer Test Suite is a comprehensive panel of two tests, MammaPrint® 70-Gene Breast Cancer Recurrence Assay and BluePrint® 80-Gene Molecular Subtyping Assay, that provide patients and their physicians with personalized breast cancer genomic profiles. These tests help them know their breast cancer and develop their personalized treatment plan.
The MammaPrint 70-Gene Assay was developed by taking samples from untreated breast cancer patients and analyzing the entire human genome. Using an outcomes based approach, researchers separated the tumors into two categories: those tumors that had a distant recurrence at 5 years and those tumors that did not recur within 5 years. By comparing the entire human genome (~25,000 genes) of the two groups of patients– researchers were able to determine the most predictive genes involved in breast cancer recurrence. A precise bioinformatics algorithm was used to determine the 70-gene expression signature that clearly and precisely identified those tumors that would likely recur in 5 years and those that would not.
Those tumors with a low likelihood of recurrence were labeled Low Risk, and those with a higher risk of recurring within 5 years were labeled High Risk. By knowing this information, newly diagnosed breast cancer patients along with their doctor can make a more informed decision about their personal treatment plan.
Furthermore, recent data published in the New England Journal of Medicine shows that 46% of patients who were considered high risk using clinical factors alone (and would most likely be recommended for chemotherapy) would be considered MammaPrint Low Risk and can safely forego chemotherapy.1
In addition to the MammaPrint test, Agendia’s Breast Cancer Suite goes a step further with the BluePrint 80-Gene Molecular Subtyping test. BluePrint looks at a tumor’s gene expression for specific molecular subtypes (Luminal, Basal, HER2) and can further assist physicians to fine tune each patient’s treatment.
For more information about each of the tests in the Agendia Breast Cancer Test Suite, click on one of the links below:
 Cardoso F, van’t Veer LJ, Bogaerts J et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016; 375:717-29.